Antiphospholipid Antibodies and Outcomes Following Lung Transplantation
نویسندگان
چکیده
PurposePre-transplant antiphospholipid antibodies (aPLab), including anticardiolipin (aCL) and anti-B2 glycoprotein-I (aB2GPI), may be associated with thrombotic complications graft loss in kidney liver transplant recipients. The objective of this study was to evaluate the prevalence impact aPLab on post-operative bleeding lung recipients.MethodsThis a single center retrospective cohort patients who were evaluated transplanted between 1/1/2018-11/30/20. All candidates screened for aPLab. We compared arterial venous events, treated as combined endpoint, recipients without (Fisher's exact test). Among aPLab, we recorded major events—defined requiring blood transfusion or surgical exploration—while therapeutic prophylactic dose anticoagulation (AC).ResultsThere 100 during period, 19 (19.0%) whom had (Figure 1). these, 7 (36.8%) pre-transplant deep vein thrombosis (DVT) events. After transplant, new symptomatic DVT thromboses 20 (24.7%) (p=0.39). Ten fully anticoagulated post-transplant, either because prior Of 6 (60.0%) bleeding. One patient AC. majority (85.7%) renal replacement therapy an eGFR <30. one-year survival rate among 89.5%.ConclusionThe presence not increase events following although underpowered small moderate effects. decision anticoagulate should account other risk factors insufficiency. Pre-transplant This (AC). There 89.5%.
منابع مشابه
Sarcoidosis, race, and short-term outcomes following lung transplantation.
BACKGROUND Patients with sarcoidosis, many of whom are African American, may require lung transplantation (LT). Little is known about survival following LT for sarcoidosis. OBJECTIVE To determine short-term mortality following LT for sarcoidosis, to evaluate if survival after LT for sarcoidosis is similar to outcomes after LT for other diseases, and to investigate the impact of race on the re...
متن کاملLong-term outcomes following alemtuzumab induction in lung transplantation.
OBJECTIVES Alemtuzumab is a commonly used induction agent for solid-organ transplantation. Its use in lung transplantation with reduced immunosuppressive regimens, however, has yet to be well characterized. METHODS From November 2006 to March 2008, 20 consecutive lung transplantation patients received alemtuzumab induction with a reduced maintenance immunosuppression regimen. Twenty consecuti...
متن کاملAntiphospholipid antibodies and renal outcomes in patients with lupus nephritis.
OBJECTIVE Previous studies have documented a high frequency of thrombotic events in lupus nephritis patients with antiphospholipid (aPL) antibodies in the serum, but there is little information on the impact of serum aPL antibodies on the clinical outcome of lupus nephritis. The aims of this study were to evaluate the seroprevalence of aPL antibodies in patients with lupus nephritis and assess ...
متن کاملAntiphospholipid antibodies.
Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and may increase your risk for blood clots or pregnancy losses. If you have a history of blood clots or recurrent pregnancy losses, you may have been tested for the presence of APLAs in your blood. The purpose of this Cardiology Patient Page is to provide information for persons with APLAs about the disorder and a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Heart and Lung Transplantation
سال: 2022
ISSN: ['1053-2498', '1557-3117']
DOI: https://doi.org/10.1016/j.healun.2022.01.718